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Abstract 
Background: Human T‑lymphotropic virus 1‑associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a 
progressive disease of the central nervous system that significantly affected spinal cord, nevertheless, the pathogen‑
esis pathway and reliable biomarkers have not been well determined. This study aimed to employ high throughput 
meta‑analysis to find major genes that are possibly involved in the pathogenesis of HAM/TSP.
Results: High‑throughput statistical analyses identified 832, 49, and 22 differentially expressed genes for normal 
vs. ACs, normal vs. HAM/TSP, and ACs vs. HAM/TSP groups, respectively. The protein–protein interactions between 
DEGs were identified in STRING and further network analyses highlighted 24 and 6 hub genes for normal vs. HAM/
TSP and ACs vs. HAM/TSP groups, respectively. Moreover, four biologically meaningful modules including 251 genes 
were identified for normal vs. ACs. Biological network analyses indicated the involvement of hub genes in many vital 
pathways like JAK‑STAT signaling pathway, interferon, Interleukins, and immune pathways in the normal vs. HAM/
TSP group and Metabolism of RNA, Viral mRNA Translation, Human T cell leukemia virus 1 infection, and Cell cycle in 
the normal vs. ACs group. Moreover, three major genes including STAT1, TAP1, and PSMB8 were identified by network 
analysis. Real‑time PCR revealed the meaningful down‑regulation of STAT1 in HAM/TSP samples than AC and nor‑
mal samples (P = 0.01 and P = 0.02, respectively), up‑regulation of PSMB8 in HAM/TSP samples than AC and normal 
samples (P = 0.04 and P = 0.01, respectively), and down‑regulation of TAP1 in HAM/TSP samples than those in AC and 
normal samples (P = 0.008 and P = 0.02, respectively). No significant difference was found among three groups in 
terms of the percentage of T helper and cytotoxic T lymphocytes (P = 0.55 and P = 0.12).
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Background
HTLV-associated myelopathy/tropical spastic parapare-
sis (HAM/TSP) is a chronic neurodegenerative disease 
with progressive characteristics that disturbs the func-
tioning of the sensory and motor nerves [1]. Indeed, 
infection with HTLV-1 can lead to asymptomatic carrier 
(AC) state or two diseases including Adult T-Cell Leuke-
mia Lymphoma (ATLL) or/and HAM/TSP [2].
About 10–20 million people worldwide have been 
infected with HTLV-1 [3]. Endemic areas include the 
Middle East, Japan, the Caribbean basin, Central Africa, 
the Melanesian Islands, and South America. Only 2–5% 
of those infected with the virus develop HAM/TSP [4, 5].
Patients with HAM/TSP often have symptoms such 
as back pain, stiffness, and pain in the lower limbs, uri-
nary frequency, and progressive weakness. Mild cogni-
tive impairment is also common. The clinical signs of the 
disease imitate multiple sclerosis when the spinal cord is 
involved, such that sick people need walking aids after 
1 year of illness [6].
HTLV-1 may weaken or impair the immune system, 
which results in autoimmunity to neurons. It also pro-
vides an immunosuppressive microenvironment that 
authorizes the HTLV-1 infected cells to escape host 
immune response and causes HTLV-1-associated dis-
eases [7].
Studies on HTLV-1 as a factor that deregulates the 
host’s immune system has lasted for many years and has 
sometimes yielded polemical results. Despite various 
studies on how to treat HAM/TSP, it is still a challenge 
for clinicians [8–12]. Therefore, identifying prognostic 
biomarkers that implicated in the pathogenesis is vital 
to understand the development and progression of a dis-
ease, as well as its diagnosis and treatment. Since now, 
different genes that are involved in mTOR, NF-kappa B, 
PI3K, and MAPK signaling pathways have been known in 
the HAM/TSP cases. Also, apoptosis can occur in the cell 
nucleus of the HAM/TSP patients [2, 13, 14].
Microarray technology can simultaneously measure 
tens of thousands of genes from different tissue samples 
in a high-throughput and cost-effective manner [15]. 
However, the results may be irreproducible [16] or be 
influenced by the data perturbations [17, 18]. One pos-
sible solution to find robust information is the integra-
tion of multiple datasets which is called meta-analysis 
[19–22]. To this end, various statistical procedures are 
employed to combine and analyze the results of the inde-
pendent studies. Meta-analysis increases the validity of 
the results and makes the possible estimation of gene 
expression differences [23].
In this study, we integrated 16 datasets in three groups 
to find gene signatures  by network analysis of differen-
tially expressed genes. The results specified the genes and 
pathways, which possibly have critical roles in the devel-
opment of the HAM/TSP pathogenesis. Flow cytom-
etry was employed to determine the ratio of CD4+ to 
CD8+ and better understanding the pathogenesis of the 
virus. Moreover, the real-time PCR confirmed different 
expressions of the determined genes in the HAM/TSP 
cases versus AC and normal subjects.
Methods
Database searching and identification of eligible studies
We searched the Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) and ArrayExpress (https ://www.
ebi.ac.uk/array expre ss/) by end of 2018 to find datasets 
reporting the expression levels of miRNA and mRNA 
in the HAM/TSP and AC subjects. To find the relevant 
reports, keywords including Human T-lymphotropic 
virus 1-associated myelopathy/tropical spastic parapare-
sis, HTLV-1, TSP, HAM/TSP, asymptomatic carrier, AC, 
ACs were firstly used. The inclusion criteria were then 
research and regular studies that performed the high-
throughput microarray studies on the human subjects. 
The normal samples were also considered to compare 
with these groups. The exclusion criteria were studies 
performed on the non-human samples, cell line, and non-
blood samples. Moreover, two independent investigators 
searched and gathered data from each included study. 
The quality and consistency of the studies were evalu-
ated by the R package MetaQC (0.1.13) [24]. Finally, the 
obtained data were classified into three groups named as 
ACs vs. normal, HAM/TSP vs. normal, and HAM/TSP 
vs. ACs.
Pre‑processing and meta‑analysis
The expression data in each group were background 
corrected and quantile normalized using the Affy pack-
age implemented in R programming language (3.6.1) 
(http://www.r-proje ct.org). The datasets were integrated 
Conclusions: High‑throughput data integration disclosed novel hub genes involved in important pathways in virus 
infection and immune systems. The comprehensive studies are needed to improve our knowledge about the patho‑
genesis pathways and also biomarkers of complex diseases.
Keywords: HTLV‑1, HTLV‑1‑associated myelopathy/tropical spastic paraparesis, HAM/TSP, High‑throughput data 
integration, Meta‑analysis, Microarray
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individually at miRNA and mRNA levels using random 
effect method (REM) and then differentially expressed 
miRNAs (DEMs) and differentially expressed genes 
(DEGs) were identified by the R package MetaDE (1.0.5), 
respectively. The low number of DEGs caused that the 
p-values of less than 0.005 and logFC > |1| were fur-
ther considered as a significant difference to have more 
DEGs and networks construction. The experimentally 
validated targets of each DEMs were obtained using miR-
TarBase (http://miRTa rBase .cuhk.edu.cn/) [25] and then 
integrated super-horizontally with DEGs. The common 
genes were considered for further analysis.
Networks construction
To construct the network comprises protein–protein 
interactions (PPIs) in each group, the STRING data-
base version 11.0 was employed [26]. Seven interaction 
sources including physical interactions, functional asso-
ciation, high-throughput experiments, genomic context, 
co-expression, databases, and text-mining were consid-
ered. Then, the PPIs networks were analyzed in terms 
of degree by NetworkAnalyzer in Cytoscape 3.7.1. The 
degree is defined as the number of edges connected to a 
node [27]. The genes with higher aforementioned criteria 
were considered as hub genes.
Module finding and pathways analysis
The ACs vs normal network clustering was implemented 
using the fast unfolding clustering algorithm in Gephi 
(0.9.2) [2, 28, 29]. The biologically meaningful modules 
were then chosen. The networks and modules were visu-
alized by Cytoscape (3.7.1). To find the meaningful path-
ways in which hub genes are involved, g:Profiler web tool 
(version: 1185_e69_eg16) was employed [30]. The over-
all expressed gene lists for each group were considered 
as the background. Ten top pathway terms with higher 
P-value were selected for further interpretations.
Patient population and sample collection
The blood samples were collected from eight patients 
with ACs, eight patients with HAM/TSP, and eight nor-
mal samples who referred to the neurology department 
of Ghaem Hospital, Mashhad University of Medical 
Sciences (MUMS). All specimens were collected after 
acquiring informed consent from the patient’s guard-
ians. Two trained neurologists affirmed the diagnosis 
of HAM/TSP according to WHO criteria. All contribu-
tors had seropositive test for HTLV-1 by enzyme-linked 
immunosorbent assay (ELISA, Diapro, Italy). The results 
of serology were confirmed by PCR [31]. The partici-
pants had no history of treatment with IFNs. This study 
was approved by the Ethics Committee of Biomedical 
Research at TUMS (IR.TUMS.SPH.REC.1396.242).
Flow cytometry analysis
To determine T helper and cytotoxic cells populations 
in HAM/TSP, ACs and normal groups; PerCP anti CD3 
antibody (bio legend company cat no: 344813), Phico-
erythrin (PE) anti CD4 antibody (bio legend company 
cat no: 317409) and PE anti CD8 antibody (bio legend 
company cat no: 301007) were used. Fresh peripheral 
blood samples were treated by lysis buffer for destroy-
ing the red blood cells and platelets. Samples were ana-
lyzed on a FACS caliber Becton Dichinson. All analyses 
were done in the lymphocyte gate.
HTLV‑1 proviral Load
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from EDTA-treated blood samples using Ficoll 
density gradient medium (Cedarlane, Hornsby, ON, 
Canada). The commercial blood mini kit (Qiagen, Ger-
many) was applied to extract DNA from PBMCs. In 
order to measure the PVL of HTLV-I in PBMCs, a real-
time PCR using a commercial real-time-based absolute 
quantification kit (HTLV-1 RG; Novin Gene, Karaj, 
Iran) was performed [32].
Quantitative real‑time PCR
Total RNA was extracted from fresh PBMCs using 
TriPure isolation reagent (Roche, Germany) according 
to the manufacturer’s instructions. Double-stranded 
cDNA was synthesized using the RevertAid TM first-
strand cDNA synthesis kit (Fermentas, Germany). Fol-
lowing primers and probes were designed and used 
to determine the expression levels of STAT1, PSMB8, 
TAP1 : STAT1 (forward primer: 5ʹ-AAC ATG GAG GAG 
TCC ACC AATG-3ʹ, reverse primer: 5ʹ-GAT CAC CAC 
AAC GGG CAG AG-3ʹ and TaqMan probe: FAM- TCT 
GGC GGC TGA ATT TCG GCA CCT -BHQ1), PSMB8 
(forward primer: 5ʹ-GTT CAG ATT GAG ATG GCC 
CATG-3ʹ, reverse primer: 5ʹ-CGT TCT CCA TTT CGC 
AGA TAG TAC -3ʹ and TaqMan probe: FAM- CCA CCA 
CGC TCG CCT TCA AGT TCC -BHQ1), TAP1 (forward 
primer: 5ʹ-TAC CGC CTT CGT TGT CAG TTATG-3ʹ, 
reverse primer: 5ʹ-GAG CCC AGG CAG CCT AGA AG-3ʹ 
and TaqMan probe: Fam-CGC ACA GGG TTT CCA 
GAG CCGCC-BHQ1). The primers and probes of Tax 
and HBZ were synthesized according to published data 
[33]. The relative 2 standard curves real-time PCR was 
carried out on the cDNA samples using TaqMan master 
mix (Takara, Otsu, Japan) and a Q-6000 machine (Qia-
gen, Germany). The GAPDH gene was employed as a 
housekeeping gene to normalize the mRNA expression 
levels, and also to control the error between samples 
[32, 34].
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Statistical analysis
Statistical analysis was carried out using GraphPad Prism 
Software Version 7 (GraphPad software, Inc). Quantita-
tive data were expressed as mean ± SEM and percent-
ages. The comparisons between various groups were 
accomplished using ANOVA. Pearson’s or Spearman’s 
tests were used for the analysis of the correlation between 
variables. The outcomes were considered significant if 
P ≤ 0.05.
Results
Studies included in the meta‑analysis
According to our  inclusion/exclusion criteria, 16 stud-
ies were found in the GEO repository datasets which 
were performed at mRNA or miRNA levels. After qual-
ity control done by MetaQC package, seven (GSE29312 
[35], GSE29332 [35], GSE46518 [36], GSE52244 [37], 
GSE55851 [38], GSE11577 [39], GSE46345 [36], three 
(GSE19080, GSE29312, GSE29332), and four (GSE38537 
[40], GSE29312, GSE29332, GSE19080) mRNA and 
miRNA datasets were of high quality for further analy-
ses of normal vs. ACs, normal vs. HAM/TSP, and ACs vs. 
HAM/TSP groups, respectively (Table 1).
Differentially expressed genes and miRNAs
A total of four miRNAs including hsa-mir-218, hsa-
mir-206, hsa-mir-31, and hsa-mir-34A were identified as 
DEMs between normal and AC group. The target genes 
of the mentioned DEMs were further identified in miR-
TarBase. A total of 663 genes were identified as target and 
added to 180 DEGs obtained across microarray datasets. 
After removing duplicate genes, 832 DEGs were speci-
fied. Also, a total of 49 and 22 genes were identified as 
DEGs for normal vs. HAM/TSP and ACs vs. HAM/TSP 
groups, respectively (Additional file 1: Table S1).
Protein‑protein interactions networks (PPINs) and Module 
finding
To explore more information about the relationships 
between the DEGs, PPINs were constructed by STRING. 
The networks were analyzed in terms of topology and 
centrality parameters. The nodes with a higher degree 
and betweenness were selected as hub genes. From these 
analyses, 24 and 6 hub genes were specified for normal vs. 
HAM/TSP and ACs vs. HAM/TSP groups, respectively 
(Fig. 1a, b). The highly connected network of the Normal 
vs. AC group caused that the modules were explored. A 
total of 23 modules were identified, which four of them 
including 251 genes were highly connected and biologi-
cally meaningful (Fig. 2a–d).
The color of each node in network is representative of 
the degree level from bold to pale color, which in turn 
shows the important role of that node in the network.
Pathway enrichment
In order to find the biological pathway controlled by 
nodes of each network, the enrichment analysis was 
carried out. The modules identified from Normal vs. 
AC group enriched in the following pathways: Mod-
ule 1: Metabolism of RNA, mRNA Splicing, RNA 
Table 1 Selected studies included in the meta-analysis
Row Normal vs. ACs Type Tissue Number of samples
1 GSE29312 Expression profiling by array Whole Blood Normal: 9, ACs: 20
2 GSE29332 Expression profiling by array Whole Blood Normal: 8, ACs: 17
3 GSE46518 Expression profiling by array CD4+ Normal: 6, ACs: 6
4 GSE52244 Expression profiling by array CD4+ Normal: 3, ACs: 3
5 GSE55851 Expression profiling by array CD4+ Normal: 3, ACs: 6
6 GSE11577 Non‑coding RNA profiling by array PBMCs Normal: 3, ACs: 4
7 GSE46345 Non‑coding RNA profiling by array CD4 + and CD8 + Normal: 12, ACs: 12
Row Normal vs. TSP Type Tissue Number of samples
1 GSE19080 Expression profiling by array CD4+ Normal: 8, HAM/TSP: 12
2 GSE29312 Expression profiling by array Whole Blood Normal: 9, HAM/TSP: 10
3 GSE29332 Expression profiling by array Whole Blood Normal: 8, HAM/TSP: 10
Row ACs vs. TSP Type Tissue Number of samples
1 GSE38537 Expression profiling by array CD4+ ACs: 4, HAM/TSP: 4
2 GSE29312 Expression profiling by array Whole Blood ACs: 20, HAM/TSP: 10
3 GSE29332 Expression profiling by array Whole Blood ACs: 17, HAM/TSP: 10
4 GSE19080 Expression profiling by array CD4+ ACs: 11, HAM/TSP: 12
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transport, HIV Infection, Rev-mediated nuclear export 
of HIV RNA, Infectious disease, Viral Messenger RNA 
Synthesis, and mRNA Processing; Module 2: rRNA pro-
cessing, Metabolism of RNA, Viral mRNA Translation, 
Infectious disease, and Ribosome biogenesis in eukary-
otes; Module 3: MicroRNAs in cancer, RNA Polymer-
ase II Transcription, Pathways in cancer, Cell cycle, 
Signaling by NOTCH, Regulation of RUNX1 Expres-
sion and Activity, p53 signaling pathway, Human T-cell 
leukemia virus 1 infection, Transcriptional regulation 
by RUNX1, and Transcriptional misregulation in can-
cer; Module 4: Ubiquitin mediated proteolysis, Class 
I MHC mediated antigen processing & presentation, 
Antigen processing: Ubiquitination & Proteasome deg-
radation, Adaptive Immune System, and Immune Sys-
tem. The nodes of Normal vs TSP group were enriched 
in Interferon Signaling, Cytokine Signaling in Immune 
system, Interferon alpha/beta signaling, Immune Sys-
tem, Interferon gamma signaling, JAK-STAT signaling 
pathway, Interleukin-6 family signaling, and Signaling 
by Interleukins. Finally, the following pathways were 
identified by enrichment of AC vs TSP group’s nodes: 
Transcriptional regulation by RUNX2 and Regulation 
of RUNX2 expression and activity (Table 2).
Demographic data
The mean age of three groups was as follow: normal con-
trols: 41 ± 2.8, ACs: 42 ± 3.5, and HAM/TSP patients: 
48 ± 3.6. Any significant difference was found between 
the ages of three groups.
Flow cytometry
Flow Cytometry Data Analyze of T helper and cytotoxic 
T lymphocytes was done by Flowjo 7.6.1. No significant 
difference was found among the three groups in terms 
of the percentage of T helper (P = 0.55) and cytotoxic T 
lymphocytes (P = 0.12) (Fig. 3).
HTLV‑1 proviral load
All HAM/TSP patients had proviral loads (PVLs) in the 
range of 216–1160 and all ACs had PVLs in the range 
of 32–140. The mean PVL of HTLV-1 in the HAM/TSP 
patients was 455.8 ± 114.7, which was significantly higher 
(P = 0.002) than that in the ACs (60.88 ± 12.92) (Fig. 4a).
Real time‑quantitative PCR for validation of expression 
changes
The expression levels of Tax and HBZ were measured in 
the samples, which revealed the insignificant up-regula-
tion of Tax in ACs group (1.41 ± 0.27) than that in HAM/
Fig. 1 The PPINs constituted between the identified hub DEGs of a Normal vs. HAM/TSP and b ACs vs. HAM/TSP groups. The color is indicative of 
the degree level, so that bold color indicates the higher degree of node
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TSP (1.22 ± 0.16) group (P = 0.42) and significant higher 
expression level of HBZ in HAM/TSP group (0.08 ± 0.01) 
than that in ACs group (0.009 ± 0.001) (P = 0.0008) 
(Fig. 4b, c).
Moreover, the network analyses revealed STAT1 and 
PSMB8 as the nodes with high degree value in normal 
vs. TSP and ACs vs. TSP groups. Therefore, we exam-
ined them with TAP1 as a random gene for further step 
of validating the meta-analysis results.  The differential 
expression of  these genes was analyzed by comparing 
expression levels in PBMCs of normal, ACs, and HAM/
TSP subjects using RT-qPCR. To this purpose, the dif-
ferential expressions of genes were analyzed by com-
paring expression levels in normal, AC, and HAM/TSP 
samples. The results revealed the meaningful down-
regulation of STAT1 in HAM/TSP (1.8 ± 0.43) samples 
than those in the AC (3.6 ± 0.52) and normal (3.3 ± 0.36) 
samples (P = 0.01 and P = 0.02, respectively) (Fig.  4d). 
The remarkable down-regulation of TAP1 in HAM/TSP 
(1.2 ± 0.27) samples than those in the AC (3.0 ± 0.56) 
Fig. 2 The PPINs constituted between the identified hub DEGs a Module 1, b Module 2, c Module 3, and d Module 4 of Normal vs. ACs group. The 
color is indicative of the degree level, so that bold color indicates the higher degree of node
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and normal (2.7 ± 0.61) samples was observed (P = 0.008 
and P = 0.02, respectively) (Fig. 4e). Also, the expression 
level of PSMB8 has significantly increased in the HAM/
TSP (8.5 ± 1.5) samples than those in the AC (3.8 ± 0.74) 
and normal (3.1 ± 0.61) samples (P = 0.04 and P = 0.01, 
respectively) (Fig. 4f ). Moreover, the correlation analysis 
Table 2 The biological pathway which the hub genes in each group were enriched
normal vs. ACs
Module 1 Metabolism of RNA, mRNA splicing, RNA transport, HIV Infection, Rev‑mediated nuclear export of HIV RNA, Infectious 
disease, viral messenger RNA synthesis, and mRNA processing
Module 2 rRNA processing, Metabolism of RNA, Viral mRNA Translation, Infectious disease, and Ribosome biogenesis in eukaryotes
Module 3 MicroRNAs in cancer, RNA polymerase II transcription, pathways in cancer, Cell cycle, signaling by NOTCH, regulation of 
RUNX1 expression and activity, p53 signaling pathway, human T‑cell leukemia virus 1 infection, Transcriptional regula‑
tion by RUNX1, and transcriptional misregulation in cancer
Module 4 Ubiquitin mediated proteolysis, Class I MHC mediated antigen processing & presentation, antigen processing: ubiquit‑
ination & proteasome degradation, adaptive immune system, and immune system
normal vs. HAM/TSP
Interferon signaling, cytokine signaling in immune system, interferon alpha/beta signaling, immune system, interferon gamma signaling, JAK‑STAT 
signaling pathway, interleukin‑6 family signaling, and signaling by interleukins
ACs vs. HAM/TSP
Transcriptional regulation by RUNX2 and regulation of RUNX2 expression and activity
Fig. 3 Flow cytometry data analyze of T helper and cytotoxic T LYMPHOCYTES
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was done to determine the association between  differ-
ent factors. The results indicated the significant correla-
tion between STAT1 and PVL (P = 0.04, r = 0.74) and 
also between STAT1 and PSMB8 (P = 0.03, r = 0.76) in 
ACs group. The remarkable associations were observed 
between Tax and TAP1 (P = 0.04, r = 0.73), STAT1 and 
PSMB8 (P = 0.02, r = 0.78), HBZ and PVL (P = 0.05, 
r = 0.70) in HAM/TSP group.
Discussion
Despite four decades of researches on HTLV-1, many 
questions remain regarding the pathogenicity mecha-
nism and key proteins involved in various pathological 
pathways. Moreover, it is also ambiguous which factors 
and proteins determine the final destiny of infection by 
HTLV1 toward HAM/TSP or/and ATLL, while some 
infected subjects remain in the form of asymptomatic 
carriers.
Microarray technology is widely used to analyze and 
measure gene expression at the high-throughput scale. 
Despite the high benefits of using this technology, the 
result of a population cannot be generalized to another 
population. Data integration and providing a meta-
analysis of the reported data improve the validity and 
reliability of the results. Genomics, transcriptomics, and 
proteomics data can be combined to find biomarkers and 
possible pathogenesis pathways [23].
From differential expression analysis of the miRNAs 
samples between normal and ACs groups, four miRNAs 
including hsa-mir-218, hsa-mir-206, hsa-mir-31, and hsa-
mir-34A were identified, which can be considered as bio-
markers for diagnosis of AC state.
In complying with previous reports, the identified 
DEGs were involved in the immune system of the HAM/
TSP subjects. Moreover, the involved molecular network 
as the primary model was introduced through collection 
and integration of high-throughput data. We validated 
two main hub genes of STAT1 and PSMB8, and also 
TAP1 to confirm our results.
STAT1 is an important intermediary in responding to 
IFNs. After binding IFN-I to the cellular receptor, sig-
nal transduction occurs through protein kinases which 
results in the activation of Jak kinase. It, in turn, causes 
phosphorylation of tyrosine in STAT1 and STAT2. The 
activated STATs are embedded in the dimer with ISGF3 
and IRF9 and enter the nucleus which leads to up-reg-
ulation of IFNs and enhances the antiviral response 
[41, 42]. The significant down-regulation of STAT1 in 
patients with HAM/TSP was observed compared with 
Fig. 4 a HTLV‑I‑ proviral load. The PVL in HAM/TSP patients was significantly higher than in ACs (P = 0.002). b Tax gene expression. No significant 
difference was found between ACs and HAM/TSP groups (P = 0.42). c HBZ gene expressions which was significantly higher in the HAM/TSP group 
than that in the ACs group (P = 0.0008). d STAT1 gene expressions in the Normal, ACs, and HAM/TSP groups. STAT1 gene expression in the HAM/TSP 
was significantly higher than in Normal (P = 0.02). The STAT1 between AC and HAM/TSP patients was statistically different (P = 0.01). No significant 
difference was found between Normal and AC patients (P = 0.91). e TAP1 gene expressions in the Normal, ACs, and HAM/TSP groups. TAP1 gene 
expression in the HAM/TSP was significantly higher than in Normal (P = 0.02). The TAP1 between AC and HAM/TSP patients was statistically different 
(P = 0.008). No significant difference was found between Normal and AC patients (P = 0.72). e PSMB8 gene expressions in the Normal, ACs, and 
HAM/TSP groups. PSMB8 gene expression in the HAM/TSP was significantly higher than in Normal (P = 0.01). The PSMB8 between AC and HAM/TSP 
patients was statistically different (P = 0.04). No significant difference was found between Normal and AC patients (P = 0.64)
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asymptomatic carriers and healthy individuals. The 
decrease in the expression of STAT1 is the response of 
the infected cells to escape HTLV-1 from the immune 
response associated with HAM/TSP.
The expression change of STAT1 in ATLL patients has 
been reported in several studies [43]. However, no stud-
ies have addressed the dysregulation of STAT1 expres-
sion in HAM/TSP patients. The reduction of STAT1 and 
subsequent MHC-I in this disease can significantly affect 
the action of CD8 and NK cells as important cells in the 
HAM/TSP pathogenesis [44, 45].
A significant increase was observed in the expression 
of PSMB8 in patients with HAM/TSP in comparison to 
those who carry the virus and normal subjects. PSMB8 
is one of the 17 subunits essential for the synthesis of the 
20S proteasome unit [46]. The targeting of proteasome 
in the HAM/TSP disease is a known mechanism which 
affects the pathogenicity of HTLV-1 by increasing the 
activity of genes such as IKBKG [2]. PSMB8 can influence 
the immune responses due to involvement in the process 
of apoptosis [47], so its increase in patients with HAM/
TSP may be because of this function. Although previous 
studies reported the role of apoptosis in the HAM/TSP 
pathogenesis [2], there is no comprehensive information 
regarding the role of PSMB8.
TAP1 is another gene which significantly down-regu-
lated in the HAM/TSP group compared with asympto-
matic carriers and normal groups. TAP1 protein which is 
expressed by the TAP gene involves the transfer of anti-
gen from the cytoplasm to the endoplasmic reticulum to 
accompany with MHC-I. HTLV-1 seems to run out from 
the antiviral response in association with MHC-I due 
to impairment in the TAP1 function [48]. Such occur-
rence was also observed as a result of infections by other 
viruses such as EBV, CMV, and adenovirus [49]. Similar 
to STAT1, a
It is noteworthy that the immune decrease in the TAP1 
expression can also significantly affect CD8 and NK cells 
[44, 45]. Therefore, it seems that escaping from CTL-
immune response is one of the important mechanisms 
for pathogenicity in HAM/TSP; however, more accurate 
and detailed studies are needed. In HAM/TSP, the disor-
der expression of the STAT1 and TAP1 proteins can dis-
rupt the immune system.
In HAM/TSP disease, PSMB8 in associated with 
PSMB8, JAK2, STAT1, IFI35, IRF1, GBP2, IFITM1, 
HLA-B, ISG20, GBP5, SOCS1, BST2, IFNG, and 
UBE2L6 activate the Interferon Signaling pathway and 
Cytokine Signaling in Immune system. The importance 
of cytokines especially IFN-γ for the HAM ⁄TSP patho-
genesis were previously reported [50, 51].
The enrichment of modules identified from normal 
vs. ACs group revealed the involvement of hub genes 
in Infectious disease, Viral Messenger RNA Synthe-
sis, Metabolism of RNA, Pathways in Cancer, Human 
T-cell leukemia virus 1 infection, and Antigen process-
ing which activate after virus infection and asympto-
matic state. These hub genes can be more evaluated in 
further studies.
The mechanisms involved in the HAM/TSP devel-
opment are complicated, so identification of proteins 
which have different expressions than the normal group 
is critical to find the complete pathogenesis pathway 
[2].
Determining viral factors such as proviral load along 
with measuring the expression levels of Tax and HBZ 
genes will be effective in finding the virus action in the 
patient group. Moreover, host-related factors such as 
age, family history of the disease, genetics, and host 
immune status are important [52–57].
Destruction of cells in the central nervous system 
may be due to the release of inflammatory substances 
from lymphocytes produced by the immune response 
to the contaminated TCD4+ cells, which are referred as 
“bystander” damage. It is most likely the mechanism of 
tissue damage in HAM/TSP disease. In this study, there 
was no significant difference in the ratio of CD4 to CD8 
in the HAM/TSP patients than asymptomatic carriers 
and healthy subjects; however, a slight increase was 
observed in the asymptomatic carriers group in com-
parison to the HAM/TSP and healthy subjects. This 
may be due to the function of the immunity system to 
prevent virus replication and progress toward HAM/
TSP disease, but more studies with a higher sample 
size are required. Eventually, patients with HAM/TSP 
have impairment in their immune system induced by 
the HTLV-1 infection, which includes the innate and 
adaptive immunity to develop the disease and increase 
apoptosis [2].
Conclusion
We employed meta-analysis of high throughput data to 
find the involved genes in the pathogenesis mechanisms 
of HAM/TSP disease. The network analysis disclosed 
novel hub genes involved in important pathways in virus 
infection and then interferon, cytokine, interleukin, and 
immune systems. Finally, the comprehensive studies are 
needed to improve our knowledge about the pathogen-
esis pathways and also biomarkers of complex diseases.
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